TY - JOUR
T1 - Abnormalities in the glycosylation of immunoglobulin heavy chain and an H-2 transplantation antigen in a mouse myeloma mutant
AU - Weitzman, Stephen
AU - Nathenson, Stanley G.
AU - Scharff, Matthew D.
N1 - Funding Information:
This work was supported American Cancer Society.
Funding Information:
from the NIH, the NSF and the
PY - 1977/4
Y1 - 1977/4
N2 - Two mutant cell lines derived from the MPC-11 mouse myeloma synthesize immunoglobulin with abnormal heavy chains and normal light chains. The defective heavy chains have molecular weights of 38,000-42,000 (M3.11) and 50,000 daltons (ICR 11.19) as compared to 55,000 daltons of the wild-type. The glycosylation of the defective heavy chains demonstrated several unusual features: first, 30-50% of the M3.11 heavy chain contained no carbohydrate, while 100% of the wild-type and ICR 11.19 heavy chains were glycosylated; second, the glycopeptides of the M3.11 heavy chains revealed an altered gel filtration pattern when compared with the wild-type; and third, digestion with an endoglycosidase indicated that the heterogeneity of the wild-type and M3.11 glycopeptides involved structural changes in the core region of the oligosaccharide. Examination of two other glycoproteins (the major histocompatibility complex antigens) in these cell lines showed that in M3.11, the H-2D but not the H-2K product was abnormally glycosylated and contained a smaller glycopeptide. However, in a subclone of M3.11 that had lost the ability to produce immunoglobulin heavy chains, the H-2D glycopeptide had returned to wild-type size. We concluded from these studies that the defective M3.11 immunoglobulin heavy chain interfered both with its own glycosylation and the glycosylation of another protein, H-2D.
AB - Two mutant cell lines derived from the MPC-11 mouse myeloma synthesize immunoglobulin with abnormal heavy chains and normal light chains. The defective heavy chains have molecular weights of 38,000-42,000 (M3.11) and 50,000 daltons (ICR 11.19) as compared to 55,000 daltons of the wild-type. The glycosylation of the defective heavy chains demonstrated several unusual features: first, 30-50% of the M3.11 heavy chain contained no carbohydrate, while 100% of the wild-type and ICR 11.19 heavy chains were glycosylated; second, the glycopeptides of the M3.11 heavy chains revealed an altered gel filtration pattern when compared with the wild-type; and third, digestion with an endoglycosidase indicated that the heterogeneity of the wild-type and M3.11 glycopeptides involved structural changes in the core region of the oligosaccharide. Examination of two other glycoproteins (the major histocompatibility complex antigens) in these cell lines showed that in M3.11, the H-2D but not the H-2K product was abnormally glycosylated and contained a smaller glycopeptide. However, in a subclone of M3.11 that had lost the ability to produce immunoglobulin heavy chains, the H-2D glycopeptide had returned to wild-type size. We concluded from these studies that the defective M3.11 immunoglobulin heavy chain interfered both with its own glycosylation and the glycosylation of another protein, H-2D.
UR - http://www.scopus.com/inward/record.url?scp=0017738404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017738404&partnerID=8YFLogxK
U2 - 10.1016/0092-8674(77)90101-5
DO - 10.1016/0092-8674(77)90101-5
M3 - Article
C2 - 405105
AN - SCOPUS:0017738404
SN - 0092-8674
VL - 10
SP - 679
EP - 687
JO - Cell
JF - Cell
IS - 4
ER -